Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Misterbianco – page 2

46 clinical trials in Misterbianco, Italy. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Misterbianco at a glance
46
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

46 trials in Misterbianco

Open in trial search

Breast cancer

Recruiting

Study of inavolisib, palbociclib and letrozole combination for patients with advanced hormone receptor-positive, HER2-negative breast cancer with PIK3CA mutation

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Inavolisib
  • Sponsor:F. Hoffmann-La Roche AG

Pancreatic carcinoma

Recruiting

Study Comparing Gemcitabine and Paclitaxel with Drug Combination for Patients with Advanced Pancreatic Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Fondazione GONO G.I.

Adenocarcinoma gastric+4

Recruiting

Study to Determine the Best Dose of Zongertinib with Trastuzumab Deruxtecan or Trastuzumab Emtansine for Patients with Advanced HER2+ Metastatic Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Boehringer Ingelheim International GmbH

Triple negative breast cancer

Recruiting

Study of Sacituzumab Tirumotecan and Pembrolizumab for Patients with Triple-Negative Breast Cancer Post-Surgery

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Breast cancer metastatic

Recruiting

Study on Lasofoxifene, Fulvestrant, and Abemaciclib for Advanced Breast Cancer in Women and Men with ESR1 Mutation

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib

Non-small cell lung cancer

Recruiting

Study Comparing Telisotuzumab Vedotin and Docetaxel for Adults with Previously Treated Non-Squamous Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Prostate cancer

Recruiting

Study of Apalutamide and Radiation Therapy for Patients with Low Burden Metastatic Hormone Sensitive Prostate Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Apalutamide
  • Sponsor:Fondazione Radioterapia Oncologica Onlus

Study of Camizestrant for Patients with ER+/HER2- Early Breast Cancer After 2 Years of Standard Endocrine Therapy

Recruiting
Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:AstraZeneca AB

Triple negative breast cancer

Recruiting

Study of Sacituzumab Govitecan and Pembrolizumab for Patients with Triple Negative Breast Cancer with Residual Disease After Surgery and Therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Gilead Sciences Inc.

Non-small cell lung cancer stage IV

Not yet recruiting

Osimertinib and drug combination in metastatic non‑small cell lung cancer with targetable genomic driver alterations

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Universita' Degli Studi Di Torino

Breast cancer metastatic

Not yet recruiting

Personalizing treatment for patients with HR-positive, HER2-negative metastatic breast cancer using fulvestrant, elacestrant, capivasertib, capecitabine, or a drug combination.

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Centro Di Riferimento Oncologico Di Aviano

Breast cancer

Not yet recruiting

A study to evaluate if silymarin prevents liver damage caused by ribociclib in patients with hormone receptor positive, HER2-negative breast cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ribociclib
  • Sponsor:Fondazione Oncotech Impresa Sociale

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Misterbianco

What the registry says about research in the country

01 Breast Cancer Research

Extensive clinical trials focusing on hormone receptor-positive (HR+) and HER2-negative breast cancer treatments. Studies evaluate novel therapeutic combinations including targeted therapies and endocrine treatments.

  • Advanced and Metastatic Disease
  • Early-Stage Breast Cancer
  • Triple-Negative Breast Cancer

Innovative approaches combining established treatments with new compounds to improve patient outcomes.

02 Gastrointestinal Oncology

Research focusing on advanced pancreatic cancer and gastric cancer treatments, evaluating new combination therapies and maintenance strategies.

  • Pancreatic Cancer Treatments
  • Gastric Cancer Therapies
  • Combination Treatment Approaches

Studies aim to improve survival rates through innovative treatment combinations and maintenance strategies.

03 Lung Cancer Studies

Clinical trials investigating treatments for Non-Small Cell Lung Cancer (NSCLC), including targeted therapies and immunotherapy combinations.

  • Early-Stage NSCLC
  • ROS1-Positive Lung Cancer
  • Post-Surgical Treatments

Focus on personalized treatment approaches based on specific genetic markers and disease stages.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.